AI Medical Service inks research agreement with US’ MSK

AI Medical Service Inc., a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s top medical research institutes on July 27, 2023. AIM is the first Japanese company to sign a joint research agreement with MSK in the field of gastrointestinal endoscopy AI.

Content and Objective of the joint research
AIM is now working toward receiving regulatory approval in Japan for its endoscopic AI product designed to identify early-stage gastric cancer. Its collaboration with MSK will facilitate joint research to investigate the application of Japanese gastrointestinal endoscopy AI in the United States.

Gastric cancer is the fourth most common cause of cancer death worldwide, and approximately 26,000 cases of gastric cancer are newly diagnosed in the United States each year.

By collaborating with one of the world’s leading cancer centers, AIM will explore the potential of using Japanese gastrointestinal endoscopy AI for clinical practice in the United States.

Comment from CEO of AIM, Dr Tomohiro Tada
“I am very pleased that we have established a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading cancer research centers. The research will combine our firm’s expertise in endoscopic AI with the wisdom and experience of MSK physicians like Dr Mark A. Schattner and Dr. Makoto Nishimura to improve the diagnosis of gastrointestinal cancers in the United States. Our company will also utilize this collaborative research to accelerate our regulatory efforts in the United States, further advancing our mission to ‘Save Lives All Over the World.’”

Comment from Dr Mark A. Schattner
“We are very excited to partner with AIM on this exciting project. Early detection of gastric cancer is a critical unmet need that has the potential to offer very significant clinical benefit to patients. The image processing and analysis developed by AIM is very promising and we look forward to refining it and incorporating it into clinical care to improve our patients’ outcomes,” said Mark Schattner, MD, FASGE, AGAF, Chief of Gastroenterology, Hepatology & Nutrition Service, MSK.
MB Buerau